Glycoprotein IIb/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: Insights from the TRANSLATE ACS study Article

Full Text via DOI: 10.1002/ccd.27816 PMID: 30244509 Web of Science: 000461016400001

Cited authors

  • Ibrahim, Homam; Kaltenbach, Lisa A.; Hess, Connie N.; Recchia, Tammy; Effron, Mark B.; Stone, Gregg W.; Wang, Tracy Y.


  • Introduction Concomitant use of glycoprotein IIb/IIIa inhibitors (GPI) and P2Y(12) inhibitors increases bleeding risk. How GPIs are being used with faster onset, higher potency P2Y(12) inhibitors are unclear. Methods and results We studied 11,781 myocardial infarction (MI) patients treated with percutaneous coronary intervention (PCI) at 233 hospitals in the TRANSLATE ACS study (2010-2012). We used propensity matching to compare 6-week major adverse cardiac events (MACE: death, recurrent MI, stroke, or unplanned revascularization) and BARC 2+ bleeding events between patients who did and did not receive planned GPI. Planned and bailout GPI were used in 4,983 (42.2%) and 229 (4.4%) MI patients undergoing PCI, respectively. Patients receiving planned GPI were younger (58 vs. 61 years), more likely to present with STEMI (62.6% vs. 45.4%) or have stent thrombosis (4.2% vs. 2.1%, all P < 0.001) than those without planned GPI use. Planned GPI was used less often with prasugrel/ticagrelor versus clopidogrel (37.1% vs. 43.3%), or when any P2Y(12) inhibitor was given >6 hr prior to PCI versus earlier (27.8% vs. 44.4%, both P < 0.01). After propensity matching, planned GPI use was not associated with any difference in MACE (6.4% vs. 5.5% OR 1.18; 95% CI: 0.99-1.57), however, the risk of BARC 2+ bleeding was higher in patients who received planned GPI (11.3% vs. 8.7%; OR 1.34; 95% CI: 1.13-1.59). Conclusion Planned GPI use as reported by practicing physicians was prevalent between 2010 and 2012 and was associated with increased risk of bleeding but not lower MACE.

Publication date

  • 2019

International Standard Serial Number (ISSN)

  • 1522-1946

Start page

  • E204

End page

  • E210


  • 93


  • 4